Compare LCLN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCLN | NVCT |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.7M | 672.1M |
| IPO Year | 2026 | 2021 |
| Metric | LCLN | NVCT |
|---|---|---|
| Price | $23.67 | $20.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $27.07 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 342.2K | 154.3K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.20 | N/A |
| Revenue Next Year | $15.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.05 | $5.55 |
| 52 Week High | $27.55 | $29.28 |
| Indicator | LCLN | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 47.61 |
| Support Level | $22.81 | $19.78 |
| Resistance Level | $23.75 | $22.84 |
| Average True Range (ATR) | 0.87 | 1.38 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 24.10 | 57.92 |
Lincoln International Inc is an independent investment banking advisory company focused on private capital markets. The company operates its business through its two operating segments: Investment Banking Advisory and Valuations and Opinions. The Investment Banking Advisory segment offers a range of services related to mergers and acquisitions, with key areas of focus including sell-side advisory, buy-side advisory, asset sales and divestitures, restructuring, primary and secondary capital raising, and merger-related engagements. The Valuations and Opinions segment provides valuation services to investment funds and financial institutions. The majority of revenue is derived from the Investment Banking Advisory segment. Geographically, the maximum revenue is derived from the Americas.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.